Skip to main content

Advertisement

SpringerLink
Log in

SDF-1/CXCR4 signaling up-regulates survivin to regulate human sacral chondrosarcoma cell cycle and epithelial–mesenchymal transition via ERK and PI3K/AKT pathway

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Human sacral chondrosarcoma, the most common one of malignant tumors, has a potent capacity to invade locally and metastasize. Notably, CXCR4 and survivin are widely recommended as a candidate of the molecule-targeted therapy. However, the roles and associations of CXCR4 and survivin in sacral chondrosarcoma have not been well characterized. Here, we investigated CXCR4 and survivin expression in human sacral chondrosarcoma. Resected sacral chondrosarcoma specimens were available from 30 patients. In vitro human chondrosarcoma cell lines SW1353 was used. Immunohistochemistry, Western blot, RNA interference, and cell cycle analyses were conducted. Immunohistochemistry revealed that CXCR4 and survivin expressed in 83.3 and 86.7 % of sacral chondrosarcoma tissues, respectively, and both were closely associated with grade and recurrence (p < 0.05). Western blot revealed that survivin expression in SW1353 increased in a dose- and time-dependent manner following SDF-1 treatment. However, the interference with MEK/ERK and PI3K/AKT pathway affected SDF-1-induced up-regulation of survivin. Besides survivin siRNA affected cell cycle progression and the expression of epithelial–mesenchymal transition (EMT) biomarkers: Snail and N-cadherin, when compared with those of non-transfection. In conclusion, the present study shows that SDF-1/CXCR4 signaling up-regulates survivin via MEK/ERK and PI3K/AKT pathway, leading to cell cycle and EMT occurrence in human sacral chondrosarcoma. The antagonizing of CXCR4 and/or survivin might benefit patients with sacral chondrosarcoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Randall RL, Bruckner J, Lloyd C, et al. Sacral resection and reconstruction for tumors and tumor-like conditions. Orthopedics. 2005;28:307–13.

    PubMed  Google Scholar 

  2. Bergh P, Gunterberg B, Meis-Kindblom JM, et al. Prognostic factors and outcome of pelvic, sacral, and spinal chondrosarcomas: a center-based study of 69 cases. Cancer. 2001;91:1201–12.

    Article  CAS  PubMed  Google Scholar 

  3. Leone A, Costantini A, Guglielmi G, et al. Primary bone tumors and pseudotumors of the lumbosacral spine. Rays. 2000;25:89–103.

    CAS  PubMed  Google Scholar 

  4. Rhomberg W, Eiter H, Böhler F, et al. Combined radiotherapy and razoxane in the treatment of chondrosarcomas and chordomas. Anticancer Res. 2006;26:2407–11.

    CAS  PubMed  Google Scholar 

  5. Polyak K, Weinberg RA. Transition between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nature Rev Cancer. 2009;9:265–73.

    Article  CAS  Google Scholar 

  6. Mani SA, Guo W, Liao MJ, et al. The epithelial–mesenchymal transition generates cells with properties of stem cells. Cell. 2008;16:704–15.

    Article  Google Scholar 

  7. Nieto MA. Epithelial plasticity: a common theme in embryonic and cancer cells. Science. 2013;342:1234850.

    Article  PubMed  Google Scholar 

  8. Wheelock MJ, Shintani Y, Maeda M, et al. Cadherin switching. J Cell Sci. 2008;121:727–35.

    Article  CAS  PubMed  Google Scholar 

  9. Nurwidya F, Takahashi F, Murakami A, et al. Epithelial mesenchymal transition in drug resistance and metastasis of lung cancer. Cancer Res Treat. 2012;44:151–6.

    Article  PubMed Central  PubMed  Google Scholar 

  10. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial–mesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7:131–42.

    Article  CAS  PubMed  Google Scholar 

  11. Gao D, Vahdat LT, Wong S, et al. Microenvironmental regulation of epithelial–mesenchymal transitions in cancer. Cancer Res. 2012;72:4883–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. Dave B, Mittal V, Tan NM, et al. Epithelial–mesenchymal transition, cancer stem cells and treatment resistance. Breast Cancer Res. 2012;14:202.

    Article  PubMed Central  PubMed  Google Scholar 

  13. Roy I, Evans DB, Dwinell MB. Chemokines and chemokine receptors: update on utility and challenges for the clinician. Surgery. 2014;155:961–73.

    Article  PubMed  Google Scholar 

  14. Yoshie O. Chemokine receptors as therapeutic targets. Nihon Rinsho Meneki Gakkai Kaishi. 2013;36:189–96.

    Article  CAS  PubMed  Google Scholar 

  15. Li W, Chen YQ, Shen YB, et al. HIF-1α knockdown by miRNA decreases survivin expression and inhibits A549 cell growth in vitro and in vivo. Int J Mol Med. 2013;32:271–80.

    PubMed Central  PubMed  Google Scholar 

  16. Skoufias DA, Mollinari C, Lacroix FB, et al. Human survivin is a kinetochore-associated passenger protein. J Cell Biol. 2000;151:1575–82.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Lladser A, Sanhueza C, Kiessling R, et al. Is survivin the potential Achilles’ heel of cancer? Adv Cancer Res. 2011;111:1–37.

    Article  CAS  PubMed  Google Scholar 

  18. Zuryń A, Litwiniec A, Gackowska L, et al. Expression of cyclin A, B1 and D1 after induction of cell cycle arrest in the Jurkat cell line exposed to doxorubicin. Cell Biol Int. 2012;36:1129–35.

    Article  PubMed  Google Scholar 

  19. Park WH, Seol JG, Kim ES, et al. Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res. 2000;60:3065–71.

    CAS  PubMed  Google Scholar 

  20. Biliran H Jr, Wang Y, Banerjee S, et al. Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line. Clin Cancer Res. 2005;11:6075–86.

    Article  CAS  PubMed  Google Scholar 

  21. Schwindt TT, Forti FL, Juliano MA, et al. Arginine vasopressin inhibition of cyclin D1 gene expression blocks the cell cycle and cell proliferation in the mouse Y1 adrenocortical tumor cell line. Biochemistry. 2003;42:2116–21.

    Article  CAS  PubMed  Google Scholar 

  22. Payton M, Chung G, Yakowec P, et al. Discovery and evaluation of dual CDK1 and CDK2 inhibitors. Cancer Res. 2006;66:4299–308.

    Article  CAS  PubMed  Google Scholar 

  23. L’Italien L, Tanudji M, Russell L, et al. Unmasking the redundancy between Cdk1 and Cdk2 at G2 phase in human cancer cell lines. Cell Cycle. 2006;5:984–93.

    Article  PubMed  Google Scholar 

  24. Ahn SH, Jeong EH, Lee TG, et al. Gefitinib induces cytoplasmic translocation of the CDK inhibitor p27 and its binding to a cleaved intermediate of caspase 8 in non-small cell lung cancer cells. Cell Oncol (Dordr). 2014;37:377–86.

    Article  CAS  Google Scholar 

  25. Xu J, Lamouille S, Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res. 2009;19:156–72.

    Article  CAS  PubMed  Google Scholar 

  26. Wendt MK, Allington TM, Schiemann WP. Mechanisms of the epithelial–mesenchymal transition by TGF-beta. Future Oncol. 2009;5:1145–68.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  27. Miyazono K. Transforming growth factor-beta signaling in epithelial–mesenchymal transition and progression of cancer. Proc Jpn Acad Ser B Phys Biol Sci. 2009;85:314–23.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

We gratefully thank other members of our Lab for their critical reading of this paper and valuable suggestions.

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Department of Orthopedics and Traumatology, Nanfang Hospital, Southern Medical University, 1838#, North of Guangzhou Avenue, Guangzhou, 510515, Guangdong, People’s Republic of China

    Peng Yang & Gang Wang

  2. Department of Orthopedics, The Second Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia, People’s Republic of China

    Peng Yang, Hongjun Huo, Yan Zhao & Yuanhang Liu

  3. Department of Orthopedics, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia, People’s Republic of China

    Qiang Li

  4. Department of Orthopedics, Inner Mongolia Hohhot First Hospital, Hohhot, Inner Mongolia, People’s Republic of China

    Yuanhang Liu

Authors
  1. Peng Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gang Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hongjun Huo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Qiang Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yan Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yuanhang Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gang Wang.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yang, P., Wang, G., Huo, H. et al. SDF-1/CXCR4 signaling up-regulates survivin to regulate human sacral chondrosarcoma cell cycle and epithelial–mesenchymal transition via ERK and PI3K/AKT pathway. Med Oncol 32, 377 (2015). https://doi.org/10.1007/s12032-014-0377-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-014-0377-x

Keywords

Search

Navigation